Lynda Bélanger1, Allison G Harvey2, Émilie Fortier-Brochu3, Simon Beaulieu-Bonneau3, Polina Eidelman2, Lisa Talbot2, Hans Ivers3, Kerrie Hein2, Manon Lamy3, Adriane M Soehner4, Chantal Mérette5, Charles M Morin6. 1. École de psychologie, Université Laval and Centre Hospitalier Universitaire de Québec. 2. Department of Psychology, University of California, Berkeley. 3. École de psychologie, Université Laval and Institut Universitaire en Santé Mentale de Québec. 4. Department of Psychiatry, School of Medicine, University of Pittsburgh. 5. Département de psychiatrie et de neurosciences, Université Laval and Centre de recherche de l'Institut Universitaire en Santé Mentale de Québec. 6. École de psychologie, Université Laval and Centre de recherche de l'Institut Universitaire en Santé Mentale de Québec.
Abstract
OBJECTIVE: To evaluate the impact of comorbid anxiety or depressive disorders on treatment response to cognitive-behavior therapy (CBT) for insomnia, behavior therapy (BT), or cognitive therapy (CT). METHOD: Participants were 188 adults (117 women; Mage = 47.4 years) with chronic insomnia, including 45 also presenting a comorbid anxiety or mild to moderate depressive disorder. They were randomized to BT (n = 63), CT (n = 65), or CBT (n = 60). Outcome measures were the proportion of treatment responders (decrease of ≥8 points on the Insomnia Severity Index; ISI) and remissions (ISI score < 8) and depression and anxiety symptoms. RESULTS: Proportion of treatment responders and remitters in the CBT condition was not significantly different between the subgroups with and without comorbidity. However, the proportion of responders was lower in the comorbidity subgroup compared to those without comorbidity in both the BT (34.4% vs. 81.6%; p = .007) and CT (23.6% vs. 57.6%; p = .02) alone conditions, although remission rates and prepost ISI change scores were not. Pre to post change scores on the depression (-10.6 vs. -3.9; p < .001) and anxiety measures (-9.2 vs. -2.5; p = .01) were significantly greater in the comorbidity subgroup relative to the subgroup without comorbidity but only for those treated with the full CBT; no difference was found for those treated with either BT or CT alone. CONCLUSIONS: The presence of a comorbid anxiety or mild to moderate depressive disorder did not reduce the efficacy of CBT for insomnia, but it did for its single BT and CT components when used alone. (PsycINFO Database Record (c) 2016 APA, all rights reserved).
RCT Entities:
OBJECTIVE: To evaluate the impact of comorbid anxiety or depressive disorders on treatment response to cognitive-behavior therapy (CBT) for insomnia, behavior therapy (BT), or cognitive therapy (CT). METHOD:Participants were 188 adults (117 women; Mage = 47.4 years) with chronic insomnia, including 45 also presenting a comorbid anxiety or mild to moderate depressive disorder. They were randomized to BT (n = 63), CT (n = 65), or CBT (n = 60). Outcome measures were the proportion of treatment responders (decrease of ≥8 points on the Insomnia Severity Index; ISI) and remissions (ISI score < 8) and depression and anxiety symptoms. RESULTS: Proportion of treatment responders and remitters in the CBT condition was not significantly different between the subgroups with and without comorbidity. However, the proportion of responders was lower in the comorbidity subgroup compared to those without comorbidity in both the BT (34.4% vs. 81.6%; p = .007) and CT (23.6% vs. 57.6%; p = .02) alone conditions, although remission rates and prepost ISI change scores were not. Pre to post change scores on the depression (-10.6 vs. -3.9; p < .001) and anxiety measures (-9.2 vs. -2.5; p = .01) were significantly greater in the comorbidity subgroup relative to the subgroup without comorbidity but only for those treated with the full CBT; no difference was found for those treated with either BT or CT alone. CONCLUSIONS: The presence of a comorbid anxiety or mild to moderate depressive disorder did not reduce the efficacy of CBT for insomnia, but it did for its single BT and CT components when used alone. (PsycINFO Database Record (c) 2016 APA, all rights reserved).
Authors: Rachel Manber; Jack D Edinger; Jenna L Gress; Melanie G San Pedro-Salcedo; Tracy F Kuo; Tasha Kalista Journal: Sleep Date: 2008-04 Impact factor: 5.849
Authors: Denise C Jarrin; Hans Ivers; Manon Lamy; Ivy Y Chen; Allison G Harvey; Charles M Morin Journal: J Sleep Res Date: 2018-03-01 Impact factor: 3.981
Authors: Andrea N Goldstein-Piekarski; Bailey Holt-Gosselin; Kathleen O'Hora; Leanne M Williams Journal: Neuropsychopharmacology Date: 2019-08-19 Impact factor: 7.853
Authors: Alix Mellor; Kellie Hamill; Melissa M Jenkins; Donald H Baucom; Peter J Norton; Sean P A Drummond Journal: Trials Date: 2019-05-08 Impact factor: 2.279
Authors: Kathleen Patricia O'Hora; Raquel A Osorno; Dena Sadeghi-Bahmani; Mateo Lopez; Allison Morehouse; Jane P Kim; Rachel Manber; Andrea N Goldstein-Piekarski Journal: JMIR Res Protoc Date: 2022-03-14
Authors: Gustavo Ivan Torres-Granados; Rafael Santana-Miranda; Andrés Barrera-Medina; Copytzy Cruz-Cruz; Ulises Jiménez-Correa; Leon Rosenthal; Francisco López-Naranjo; Juan Manuel Martínez-Núñez Journal: Sleep Biol Rhythms Date: 2022-08-12 Impact factor: 1.390
Authors: Susanne Hagatun; Øystein Vedaa; Allison G Harvey; Tine Nordgreen; Otto R F Smith; Ståle Pallesen; Odd E Havik; Frances P Thorndike; Lee M Ritterband; Børge Sivertsen Journal: Internet Interv Date: 2018-02-21